Last reviewed · How we verify
NCT03181997: TOP-AS
Outcomes of Transcatheter Aortic Valve Implantation in Oncology Patients With Severe Aortic Stenosis
trial testing Native aortic valve in Aortic Valve Stenosis in 168 participants. Completed in 1 March 2019.
1 March 2019
Quick facts
| Lead sponsor | Rabin Medical Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 168 |
| Start date | 1 January 2017 |
| Primary completion | 1 March 2019 |
| Estimated completion | 1 March 2019 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- Native aortic valve
- Transcatheter aortic valve implantation (TAVI)
Conditions studied
- Aortic Valve Stenosis — all drugs for Aortic Valve Stenosis →
- Malignancy — all drugs for Malignancy →
Sponsor
Rabin Medical Center
Who can join
Eligibility, any sex, with Aortic Valve Stenosis or Malignancy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
As for today, transcatheter aortic valve implantation (TAVI) is indicated only in symptomatic patients with severe aortic stenosis (AS) at high surgical risk. As cancer therapy improves, some AS patients suffering active malignancy (including advanced metastatic diseases) may be more endangered by their untreated valvular disease than their oncological disease. Among these patients, TAVI may be indicated before cancer related surgery or cardiotoxic anti-cancer therapy in order to achieve better anti-cancer therapy outcomes. Individualized life expectancy assumptions should be evaluated by the heart team in the clinical decision-making process as an essential factor in weighing the risk-benefit ratio for oncologic patients undergoing TAVI. A multicenter, international TAVI in Oncology Patients with AS (TOP-AS) registry was designed to collect data on patients with an active malignancy and severe AS undergoing TAVI. The aim of the study is to evaluate the outcomes, benefits and risks of oncology patients undergoing TAVI, mainly the patients' survival and cause of death and also the interactions between the valvular and the oncologic conditions.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Transcatheter Aortic Valve Replacement in Oncology Patients With Severe Aortic Stenosis.
Landes U, Iakobishvili Z, Vronsky D, Zusman O, et al · · 2019 · cited 61× · PMID 30621982 · DOI 10.1016/j.jcin.2018.10.026
Verify or expand the search:
- PubMed search for NCT03181997
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Aortic Valve Stenosis
Currently open trials in the same condition.
- NCT07455292 — Phenotyping Left Ventricle Failure With Hemodynamic Biomarkers From 4D Flow Magnetic Resonance Imaging · NA · recruiting
- NCT07008911 — CardioHeartConnect: Commercially Available Fitness for Cardiac Rehabilitation · NA · recruiting
- NCT07145463 — Prospective, Multicenter, Randomized Controlled Clinical Study Evaluating the VitaFlow Liberty® Flex Transcatheter Aorti · NA · recruiting
- NCT07520656 — Impact of Transcatheter Aortic Valve Implantation and Mitral Valve Repair on Sleep-Disordered Breathing · recruiting
- NCT07267117 — Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease · recruiting
Other Rabin Medical Center trials
Trials by the same sponsor.
- NCT06837909 — Transversus Abdominis Plane Block Versus Wound Infiltration for Pulmonary Function Preservation Following Laparoscopic L · NA · recruiting
- NCT06951399 — Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT07208240 — Tb-PSMA-I&T Radionuclide Before Radical Prostatectomy in Patients With Locally Advanced Prostate Cancer - TbeforePROST T · Phase 1, PHASE2 · recruiting
- NCT06931119 — Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients · Phase 1 · not yet recruiting
- NCT06966427 — Prospective Evaluation of a Dose Guidance System for People With Diabetes Initiating Basal Insulin or Using Insulin Inje · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03181997 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rabin Medical Center
- Last refreshed: 28 March 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03181997.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing